Martek S&P MidCap
This article was originally published in The Tan Sheet
Executive Summary
Columbia, Md.-based firm will be added to Standard & Poor's MidCap 400 index after the close of trading March 1, Martek announces Feb. 25; the index covers roughly 7% of the U.S. equities market. CEO Henry Linsert says Martek's addition "should broaden the company's exposure to investors." Martek signed a license and supply agreement with Kellogg earlier this month (1"The Tan Sheet" Feb. 14, 2005, In Brief)...
You may also be interested in...
Martek/Kellogg agreement
Columbia, Md.-based firm announces a 15-year, non-exclusive docosahexaenoic acid (DHA) license and supply agreement with Kellogg Feb. 4, with the first DHA-fortified food product scheduled for launch in mid-2006. Kellogg will develop foods containing Martek's DHA and "must purchase, subject to certain exceptions, almost all of its DHA from Martek" for products in the U.S., as well as "display the Martek DHA logo on all product packages, print advertisements and certain other promotional materials." Martek has supply agreements with Mead Johnson and Nestle to provide DHA for infant formula...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.